Home Featured Page 254

Featured

Latest

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

atai Launches Revixia Life Sciences to Develop Salvinorin A for a...

Awakn Life Sciences Begins Trading on the OTCQB(R) Venture Market Under...

Mindset Pharma Announces Publication of Three PCT Patent Applications for Its...

atai Life Sciences Reports Second Quarter 2021 Financial Results and Business...

Beckley Psytech completes oversubscribed $80m (£58m) fundraise to develop portfolio of...

Modernization of Sacred Plant Medicine Traditions: At What Cost?

PT256 – Matthew D. Segall, Ph.D. – Consciousness, Capitalism, and Philosophy

PTSF70 – Depth Psychology, The Reach of the DEA, and Progress...

Psychedelics, Religion, and the DEA’s Quest for Soul

PT255 – Jasmine Virdi – Conservation, Covid, and Neurodivergence

EDITOR PICKS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Who Gets to Heal?

atai Launches Revixia Life Sciences to Develop Salvinorin A for a...

Awakn Life Sciences Begins Trading on the OTCQB(R) Venture Market Under...

Mindset Pharma Announces Publication of Three PCT Patent Applications for Its...

atai Life Sciences Reports Second Quarter 2021 Financial Results and Business...

Beckley Psytech completes oversubscribed $80m (£58m) fundraise to develop portfolio of...

Modernization of Sacred Plant Medicine Traditions: At What Cost?

PT256 – Matthew D. Segall, Ph.D. – Consciousness, Capitalism, and Philosophy

PTSF70 – Depth Psychology, The Reach of the DEA, and Progress...

Psychedelics, Religion, and the DEA’s Quest for Soul

PT255 – Jasmine Virdi – Conservation, Covid, and Neurodivergence

EDITOR PICKS

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY